- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT02308306
Predictive Markers of the Effects of Opioid Therapy (ABILITY)
Predictive Markers of the Effects of Opioid Therapy in Opioid naïve Patients With Chronic Pain: an International, Multi-centre, Observational Cohort Study (ABILITY)
The overall goal of the ABILITY study is to help improve pain diagnostics and treatment by developing an implementable clinical computerised decision support system based on individual patient characteristics.
The investigators hypothesize that successful pain control with opioids can be predicted before treatment initiation with advanced data analyses of data originating from pre-treatment EEG, QST and pain-related catastrophic thinking.
The primary objective of this study is the identification of markers that can be used to individualize treatment recommendations, i.e. to reliably predict the response of pain to opioids.
Markers are selected among the most promising data and machine-learning methods are used for the prediction. This includes determining the associations between a battery of selected pre-treatment clinical predictive markers and the analgesic effect of opioid treatment in opioid naïve chronic pain patients, including indication and responder identification.
The key secondary objectives are as follows: to investigate pre-treatment clinical predictive markers as predictors of opioid treatment efficacy and effectiveness in terms of the following:
- Pain intensity and unpleasantness
- Use of rescue analgesics
- Physical functioning
- Global improvement and satisfaction with treatment
Tutkimuksen yleiskatsaus
Tila
Opintotyyppi
Ilmoittautuminen (Todellinen)
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Pellenberg
-
Leuven, Pellenberg, Belgia, 3212
- KU Leuven and the Leuven Centre for Algology & Pain Management
-
-
-
-
-
Ljubljana, Slovenia, 1000
- Ljubljana University Medical Centre, Department of Anaesthetics and Surgical Intensive Care
-
-
-
-
-
Aarhus C, Tanska, 8000
- Department of Rheumatology, Aarhus University Hospital
-
Give, Tanska, 7323
- Friklinikken
-
Ringsted, Tanska, 4100
- Hospitalet Valdemar
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Näytteenottomenetelmä
Tutkimusväestö
Kuvaus
Inclusion Criteria:
- Pain duration ≥ 3 months.
- Minimum baseline pain intensity ≥ 4 on a 0-10 numerical rating scale (over the past week).
- Maximum baseline pain intensity < 9 on a 0-10 numerical rating scale (over the past week).
- Prescribed opioid treatment (ATC: N02)
- Anticipated to stay on prescribed opioid treatment throughout the study, i.e. >14 days.
- Anticipated to stay on any concomitant non-opioid treatment throughout the study, i.e. >14 days.
- Subject may be male or female, age >18 years old.
- Is willing and able to comply with study procedures as judged by the site investigator.
- Subject has voluntarily signed and dated the study-specific informed consent form, approved by an Independent Ethics Committee, after the nature of the study has been explained and the subject has had the opportunity to ask questions. The informed consent form must be signed before any study-specific procedures are performed.
Exclusion Criteria:
- Has a mental incapacity or language barriers precluding adequate understanding of study procedures.
- Is considered by the site investigator unsuitable to participate in the study for any other reason, for instance due to a significant serious underlying condition.
- Recently received opioids on a daily basis (within the last 10 weeks).
- Current alcohol or substance abuse, according to the site investigator's medical judgement.
- Is anticipated to undergo a painful procedure(s) (e.g. surgery) during the study, which can interfere with the experience of the chronic pain condition for which the subject is to receive opioids.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Havaintomallit: Kohortti
- Aikanäkymät: Tulevaisuuden
Kohortit ja interventiot
Ryhmä/Kohortti |
---|
Opioid analgesics
Opioid treatment is determined, prescribed, modified and discontinued at the sole discretion of the treating physician at each research site; regardless of generic name, manufacturer, constituent components, route of administration, and dosing schedule (including titration and run-in periods).
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Reduction of chronic pain assessed by 0-10 numerical rating scale (NRS) scores
Aikaikkuna: After 14-days of opioid treatment
|
The absolute and percentage change from baseline in ratings of average pain in the past week at Day 14.
Of note, a percentage change of ≥30% is considered clinically significant.
|
After 14-days of opioid treatment
|
Improvement of health-related quality of life assessed by QLQ-C30 scores
Aikaikkuna: After 14 days of opioid treatment
|
The absolute and percentage change from baseline in ratings of health-related quality of life in the past week at Day 14.
A subjectively significant change in QLQ-C30 scores is one that is ≥10 from baseline.
|
After 14 days of opioid treatment
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
BPI worst pain in the past week
Aikaikkuna: Day 14 post-treatment
|
Change from baseline
|
Day 14 post-treatment
|
BPI least pain in the past week
Aikaikkuna: Day 14 post-treatment
|
Change from baseline
|
Day 14 post-treatment
|
BPI current pain in the past week
Aikaikkuna: Day 14 post-treatment
|
Change from baseline
|
Day 14 post-treatment
|
BPI pain severity in the past week
Aikaikkuna: Day 14 post-treatment
|
Change from baseline
|
Day 14 post-treatment
|
BPI pain interference score
Aikaikkuna: Day 14 post-treatment
|
Change from baseline
|
Day 14 post-treatment
|
Improvement score
Aikaikkuna: Day 14 post-treatment
|
Proportion with score >4
|
Day 14 post-treatment
|
Concomitant and rescue medication
Aikaikkuna: Until 14 days post-treatment
|
Until 14 days post-treatment
|
|
Adverse events
Aikaikkuna: Until 14 days post-treatment
|
Number (%) of the following:
|
Until 14 days post-treatment
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Opintojen puheenjohtaja: Asbjørn M Drewes, MD, PhD, DMSci, Aalborg University Hospital, Denmark
- Opintojohtaja: Anne E Olesen, MSc (Pharm), PhD, Aalborg University Hospital, Denmark
- Opintojohtaja: Kasper Grosen, MHSc, PhD, Aarhus University / Aarhus University Hospital, Denmark
- Päätutkija: Mogens Pfeiffer-Jensen, MD, PhD, Aarhus University Hospital, Denmark
- Päätutkija: Michael Kamp-Jensen, MD, PhD, Hospitalet Valdemar, Denmark
- Päätutkija: Bart Morlion, MD, PhD, University of Leuven / University Hospitals Leuven, Belgium
- Päätutkija: Gorazd Pozlep, MD, Ljubljana University Medical Centre, Slovenia
- Päätutkija: Torsten Jonsson, MD, Hospitalet Valdemar, Denmark
Julkaisuja ja hyödyllisiä linkkejä
Hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Arvio)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- ABILITY
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Krooninen kipu
-
Alanya Alaaddin Keykubat UniversityValmisSterilointi, tubal | Visual Analog Pain Scale
-
Korea University Anam HospitalKorea UniversityValmisKivun mittaus | Visual Analog Pain Scale
-
Jules Bordet InstituteMacopharma; Belgian Hematological SocietyRekrytointiRefractory Chronic Graft versus Host Disease (cGVHD)Belgia
-
Turkish Ministry of Health, Kahramanmaras Provincial...Rekrytointi
-
Fujian Cancer HospitalEi vielä rekrytointiaHawthorn Red Combined Refractory Cancer Pain
-
Sobet AGLa Tour Hospital; Klinikum Klagenfurt am Wörthersee; Krankenhaus der Elisabethinen... ja muut yhteistyökumppanitRekrytointiMyofascial Pain Syndrome - Alaselkä | Myofascial Pain Syndrome - Niska | Myofascial Pain Syndrome - jännityspäänsärkyItävalta, Sveitsi
-
Ankara UniversityValmisKivun mittaus | Visual Analogue Pain ScaleTurkki
-
East Carolina UniversityPeruutettu
-
Yuzuncu Yıl UniversityValmisMyofascial Pain Disfunction -oireyhtymä, temporomandibulaarinen nivelTurkki
-
Washington University School of MedicinePeruutettuBruksismi | Temporomandibulaariset nivelsairaudet | Temporomandibulaarinen nivelen toimintahäiriö | Myofascial Pain Disfunction -oireyhtymä, temporomandibulaarinen nivelYhdysvallat